600 patients66,869 observations120 daysLIVE

Patient P-01678

Synthetic patientNBL-101 · Day 116 · 45–54 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Stable
GI state
Favorable
Inflammatory state
Stable
Nutritional resilience
Declining
Discontinuation risk
55%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S14
  2. Day 31 NP-02 recommendedDietary Support Protocol NP-02
  3. Day 32 Patient acceptedStarted NP-02 in the companion
  4. Day 42 GI symptom burden −17% vs expectedDietary Support Protocol NP-02
  5. Day 46 Trajectory diverged from predictionObserved response fell below the model's expected path.
  6. Day 48 Tolerance state changedUnstable → Improving
  7. Day 53 SC-12 recommendedSupportive Compound SC-12
  8. Day 54 Patient declinedNot now
  9. Day 56 GI-04 recommendedGI Support Protocol GI-04
  10. Day 57 Patient acceptedStarted GI-04 in the companion
  11. Day 65 GI symptom burden −38% vs expectedGI Support Protocol GI-04
  12. Day 71 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 46.

Primary contributors, last 14 days
  • Nutritional resilience-7
  • Inflammatory activity-3
  • Treatment adherence-2

What helped?

  • Dietary Support Protocol NP-02Day 31
    Result: symptom burden −17%
  • Supportive Compound SC-12Day 53
    Declined by patient
  • GI Support Protocol GI-04Day 56
    Result: symptom burden −38%
LIFE OS recommendation
Supportive Compound SC-12
65%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 85% showed improvement
  • median effect visible after 6 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
36.3/100
stable · +1.1 vs previous 14 d
Toxicity
Blood
43.9/100
worsening · +6.7 vs previous 14 d
Sleep quality
Wearable
24.9/100
worsening · -1.9 vs previous 14 d
Energy level
Daily log
3/10
worsening · -0.4 vs previous 14 d
Stress level
Daily log
6/10
stable · +0.1 vs previous 14 d
Steps
Wearable
5,939
stable · -103 vs previous 14 d
Adherence
Companion
55.2 %
stable · +1.0 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →

Heading towards restoration · 46 from the failing basin, 43 from restoration.

Good elements to keep
  • GI Support Protocol GI-04
    intervention · steering +63.5
  • Dietary Support Protocol NP-02
    intervention · steering +26.2
Main detractors to watch
  • Low butyrate capacity
    hidden · steering -17.5
  • FUT2 non-secretor
    hidden · steering -10.6
  • Dietary fat load
    perturbation · steering -9.1
  • Histamine load
    perturbation · steering -7.8
  • Dietary fat load
    detractor · GI +5.4 next day
  • Histamine load
    detractor · GI +4.9 next day
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +5.4detractor · 95%
  • Histamine load
    +4.9detractor · 95%
  • Simple carbohydrates
    +4.4detractor · 95%
  • Insoluble fibre
    +3.8detractor · 95%
  • Alcohol
    +1.3no signal · 27%
  • Spicy / capsaicin
    -0.4no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 32/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Mucosal barrier integrity 70
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • WearableSleep 5.5 h, below personal baseline
  • Inflammatory signalling 25
    • BloodInflammatory load index 42
  • Drug metabolism and exposure 20
    • BloodToxicity index 44
  • Autonomic recovery 20
    • WearableShort sleep window
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • CYP2D6 Normal metabolizer
    Expected exposure
Microbiome
Shannon diversity 2.6 · butyrate capacity 32/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisNormal
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
48 ms
Sleep
5.8 h
Steps
6,149
Resting HR
65 bpm
Daily log: GI score 36, nutritional resilience 49, adherence 55.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Keep meals regular; three to four moderate portions spaced through the day
  • Include a cooked vegetable portion with each main meal
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Log the daily check-in; one line is enough
  • Keep the current walking rhythm
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • No additional supplements this week
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0138354%S14NP-02improved40
P-0145854%S14GI-04improved44
P-0156653%S09GI-04improved52
P-0164953%S14GI-04improved46
P-0143252%S14GI-04improved46
P-0156852%S14GI-04improved40
P-0161750%S14SC-12improved50
P-0163250%S14GI-04improved36
P-0167450%S14GI-04improved48
P-0171350%S04GI-04improved46
P-0148649%S18GI-04improved47
P-0158849%S14GI-04improved57